Active Recombinant Human CD86 protein, Fc/Avi-tagged, Biotinylated

• Cat.No.: CD86-051H
• Product Overview: Biotinylated Recombinant Human CD86(Leu26-Pro247) protein, fused to Fc/Avi tag at the C-terminus, was expressed in CHO cells .

Specification

• Description: B7-2, also known as CD86, B70, and ETC-1, is a 60-100 kDa variably glycosylated protein in the B7 family. B7 family members are transmembrane cell surface molecules that play important roles in immune activation and the maintenance of immune tolerance (1, 2). Mature human B7-2 consists of a 224 amino acid (aa) extracellular domain (ECD) with two Ig-like domains, a 21 aa transmembrane segment, and a 61 aa cytoplasmic tail (3, 4). Within the ECD, human B7-2 shares 59% aa sequence identity with mouse and rat B7-2. Alternative splicing of human B7-2 generates additional isoforms that lack both Ig-like domains or a region that includes the transmembrane segment. B7-2 is highly expressed on activated antigen presenting cells (APC), e.g. B cells, dendritic cells, and monocytes (4-7), as well as on vascular endothelial cells (8). B7-2 and the closely related B7-1/CD80 exhibit overlapping but distinct functional properties. Their binding to CD28, which is constitutively expressed on T cells, enhances T cell receptor signaling and also provides TCR-independent co-stimulation (3-5, 7, 9-11). B7-1 and B7-2 additionally bind the CD28-related protein, CTLA-4, which is up‑regulated and recruited to the immunological synapse (IS) at the onset of T cell activation (3-5, 7, 9, 10). CTLA-4 ligation inhibits the T cell response and supports regulatory T cell function (12). B7-2 is expressed earlier than B7-1 following APC activation (6), and both proteins bind with higher affinity to CTLA-4 than to CD28 (10). B7-2 promotes the stabilization of CD28 in the IS, while B7-1 is primarily responsible for promoting CTLA-4 recruitment and accumulation in the IS (13). The relative participation of B7-1 and B7-2 in T cell co-stimulation can also alter the Th1/Th2 bias of the immune response (14). Both B7-1 and B7-2 serve as cellular receptors for B species adenoviruses (15).
• Source: CHO cells
• Species: Human
• Tag: Fc&Avi
• Predicted N Terminal: Leu26
• Form: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Bio-activity: The biotin to protein ratio is greater than 0.7 as determined by the HABA assay. Measured by its binding ability in a functional ELISA. When Recombinant Human CTLA4 Fc Chimera is immobilized at 0.25 μg/mL (100 μL/well), the concentration of Biotinylated Recombinant Human CD86 Fc Chimera Avi-tag that produces 50% of the optimal binding response is 5-30 ng/mL.
• Molecular Mass: 87-101 kDa, under reducing conditions
• Protein length: Leu26-Pro247
• Endotoxin: <0.10 EU per 1 μg of the protein by the LAL method.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Applications: Bioactivity
• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.12 months from date of receipt, -20 to -70 °C as supplied.1 month, 2 to 8 °C under sterile conditions after reconstitution.3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Reconstitution: Reconstitute at 500 μg/mL in PBS.

Gene Information

• Gene Name: CD86 CD86 molecule [ Homo sapiens ]
• Official Symbol: CD86
• Synonyms: CD86; CD86 molecule; CD28LG2, CD86 antigen (CD28 antigen ligand 2, B7 2 antigen); T-lymphocyte activation antigen CD86; B lymphocyte antigen B7 2; B7 2; B7.2; BU63; FUN-1; CTLA-4 counter-receptor B7.2; B-lymphocyte activation antigen B7-2; CD86 antigen (CD28 antigen ligand 2, B7-2 antigen); B70; B7-2; LAB72; CD28LG2; MGC34413
• Gene ID: 942
• mRNA Refseq: NM_001206924
• Protein Refseq: NP_001193853
• MIM: 601020
• UniProt ID: P42081

Reviews

01/09/2022

With the CD86 protein's high-quality composition and reliability, researchers can confidently proceed with their studies, knowing that they have access to a protein that consistently delivers accurate results.

05/30/2021

Its high purity and stability ensure reliable and reproducible results, which are paramount for achieving meaningful scientific outcomes.

12/08/2017

The CD86 protein is renowned for its outstanding quality, making it an optimal choice to fulfill the requirements of my experimental investigations.

Q&As

Are there any ongoing clinical trials involving CD86 inhibitors?

Yes, several clinical trials are investigating the efficacy of CD86 inhibitors in various diseases, including autoimmune disorders and certain cancers.

How does CD86 contribute to transplant medicine?

In transplantation, CD86 blockade is investigated as a potential strategy to modulate the immune response and prevent graft rejection by inhibiting excessive T cell activation.

How does CD86 influence the balance between Th1 and Th2 immune responses?

CD86 signaling is involved in the differentiation of T helper cells. Modulating CD86 levels may influence the balance between Th1 and Th2 responses, which is relevant in various immune-mediated diseases.

Can CD86 be used as a prognostic marker in certain diseases?

There is emerging evidence suggesting that CD86 expression levels may have prognostic value in certain diseases, guiding clinicians in predicting disease outcomes.

How does CD86 influence the development of regulatory T cells (Tregs)?

CD86 signaling is involved in the development and function of regulatory T cells, which play a crucial role in maintaining immune tolerance and preventing autoimmune reactions.